Additionally, several more recent studies, targeting other TAAs such as FcRH5, ROR1, and CD3E, further confirmed that targeting membrane-proximal epitopes, which also shortened the distance between T cells and tumor cells, could improve the in vitro potency of their antibody constructs to facilitate T cell mediated target cell lysis [15,19,26]. This evidence concerns the gene FCRL5 and neoplasm.